AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

RHYTHM BIOSCIENCES LTD

0.076

-0.002-2.56%

Volume:48.78K

Turnover:3.76K

Market Cap:21.55M

PE:-8.58

High:0.078

Open:0.078

Low:0.076

Close:0.078

Loading ...

Overview Company News Filings

Rhythm Biosciences Receives Quality Certification from UK Standards Body

MT Newswires Live

Rhythm Biosciences Unit Records First Commercial Sales

MT Newswires Live

Rhythm Biosciences Appoints CFO; Shares Up 7%

MT Newswires Live

BRIEF-Rhythm Biosciences Appoints Todd Perkinson As CFO

Rhythm Biosciences Ltd - Todd Perkinson Appointed as Chief Financial Officer

THOMSON REUTERS

Rhythm Biosciences First Half 2025 Earnings: EPS: AU$0.002 (vs AU$0.018 loss in 1H 2024)

Simply Wall St.

Rhythm Biosciences Completes Initial Integration of Genetype Business

MT Newswires Live

Rhythm Biosciences Completes Genetype Business Acquisition

MT Newswires Live

Rhythm Biosciences Ltd-Completion of Genetype Risk Assessment Portfolio Acquisition

THOMSON REUTERS

BRIEF-Rhythm Biosciences Acquires Genetype Genetic Risk Assessment Business

ASX Alert-Rhy Acquires Genetype Genetic Risk Assessment Business-Rhy.ax

THOMSON REUTERS

Rhythm Biosciences Ltd - Trading Halt Requested Pending Proposed Acquisition Announcement

THOMSON REUTERS

Rhythm Biosciences Ltd-Market Update - All End of Cy24 Milestones Attained

THOMSON REUTERS

BRIEF-Rhythm Biosciences Says Susan Macleman Steps Down From Deputy Chair

Rhythm Biosciences Ltd-Board Composition Update - Ned Resignations

THOMSON REUTERS

Rhythm Biosciences Ltd - Susan Macleman Steps Down From Deputy Chair to Non-Executive Director

THOMSON REUTERS

BRIEF-Rhythm Biosciences Says To Raise A$3.5 Million At A$0.10 Per Share

Rhythm Biosciences Ltd - All Currencies in AUD

THOMSON REUTERS

Rhythm Biosciences Ltd-Strong Demand in Share Placement to Raise $3.5 Million

THOMSON REUTERS

BRIEF-Rhythm Biosciences Seeks Trading Halt

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RHY.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RHY.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHY.AU\",,,,,undefined,":{"symbol":"RHY.AU","market":"AU","secType":"STK","nameCN":"RHYTHM BIOSCIENCES LTD","latestPrice":0.076,"timestamp":1745302320000,"preClose":0.078,"halted":0,"volume":48782,"delay":0,"nameEN":"RHYTHM BIOSCIENCES LTD","floatShares":183846102,"shares":283596750,"eps":-0.008853,"marketStatus":"Closed","change":-0.002,"latestTime":"04-22 16:12:00 AEST","open":0.078,"high":0.078,"low":0.076,"amount":3758,"amplitude":0.025641,"askPrice":0.079,"askSize":100000,"bidPrice":0.071,"bidSize":51336,"shortable":3,"etf":0,"ttmEps":-0.008853,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.078,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":0.308186,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHY.AU\",,,,,undefined,":{"symbol":"RHY.AU","floatShares":183846102,"roa":"-33.68%","roe":"-71.10%","lyrEps":-0.030034,"volumeRatio":0.308186,"shares":283596750,"dividePrice":0,"high":0.078,"amplitude":0.025641,"preClose":0.078,"low":0.076,"week52Low":0.042,"pbRate":"4.42","psRate":"6.81","week52High":0.14,"institutionHeld":0,"latestPrice":0.076,"committee":-0.321563,"eps":-0.008853,"divideRate":0,"volume":48782,"delay":0,"ttmEps":-0.008853,"open":0.078,"prevYearClose":0.087,"prevWeekClose":0.078,"prevMonthClose":0.08,"prevQuarterClose":0.08,"fiveDayClose":0.078,"twentyDayClose":0.09,"sixtyDayClose":0.1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RHY.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527971450","title":"Rhythm Biosciences Receives Quality Certification from UK Standards Body","url":"https://stock-news.laohu8.com/highlight/detail?id=2527971450","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527971450?lang=en_us&edition=fundamental","pubTime":"2025-04-14 14:25","pubTimestamp":1744611942,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  said that it has retained its ISO 13485:2016 certification for the seventh year from the UK's British Standards Institution , according to a Monday filing with the Australian bourse.This year's certification also includes an expanded scope, now covering the design, manufacturing, distribution, installation, and servicing of in-vitro medical devices, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2520110961","title":"Rhythm Biosciences Unit Records First Commercial Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2520110961","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520110961?lang=en_us&edition=fundamental","pubTime":"2025-03-19 09:19","pubTimestamp":1742347152,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  said that its Genetype business recorded its first commercial sales under the company's ownership, according to a Wednesday Australian bourse filing.The company said it is forecasting an \"attractive\" sales growth profile for Genetype products over the foreseeable future, driven by potential enterprise customers and support from influential key opinion leaders, among other factors.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RHY.AU"],"gpt_icon":0},{"id":"2520510896","title":"Rhythm Biosciences Appoints CFO; Shares Up 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2520510896","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520510896?lang=en_us&edition=fundamental","pubTime":"2025-03-18 11:08","pubTimestamp":1742267303,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences (ASX:RHY) named Todd Perkinson as its Chief Financial Officer, effective Tuesday, according to a same-day filing with the Australian bourse.Perkinson most recently worked at technology company AdNeo (ASX:AD1), the filing said.Shares were up 7% in afternoon trade Tuesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AD1.AU","XJO.AU","BK7002","XAO.AU","RHY.AU","BK7124","BK7503","XKO.AU"],"gpt_icon":0},{"id":"2520317316","title":"BRIEF-Rhythm Biosciences Appoints Todd Perkinson As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2520317316","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520317316?lang=en_us&edition=fundamental","pubTime":"2025-03-18 08:55","pubTimestamp":1742259328,"startTime":"0","endTime":"0","summary":"BRIEF-Rhythm Biosciences Appoints Todd Perkinson As CFOMarch 18 (Reuters) - Rhythm Biosciences Ltd RHY.AX:TODD PERKINSON APPOINTED AS CHIEF FINANCIAL OFFICERFurther company coverage: RHY.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nFWN3Q00JB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2520828096","title":"Rhythm Biosciences Ltd - Todd Perkinson Appointed as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520828096","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520828096?lang=en_us&edition=fundamental","pubTime":"2025-03-18 06:06","pubTimestamp":1742249187,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nFWN3Q00JB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2514044965","title":"Rhythm Biosciences First Half 2025 Earnings: EPS: AU$0.002 (vs AU$0.018 loss in 1H 2024)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514044965","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514044965?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:00","pubTimestamp":1740517238,"startTime":"0","endTime":"0","summary":"Profit margin: 19% . The move to profitability was primarily driven by higher revenue.ASX:RHY Earnings and Revenue History February 25th 2025. All figures shown in the chart above are for the trailing 12 month  period. Rhythm Biosciences shares are up 3.2% from a week ago.You should always think about risks. Case in point, we've spotted   4 warning signs for Rhythm Biosciences  you should be aware of, and 1 of them is potentially serious.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rhythm-biosciences-first-half-2025-210038887.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RHY.AU"],"gpt_icon":0},{"id":"2508310289","title":"Rhythm Biosciences Completes Initial Integration of Genetype Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2508310289","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508310289?lang=en_us&edition=fundamental","pubTime":"2025-02-04 11:46","pubTimestamp":1738640790,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  completed the initial integration of the Genetype business it acquired on Dec. 24, 2024, with the commercial processes required to provide and sell the geneType genetic risk assessment product restored, according to a Tuesday Australian bourse filing.The integration was expected to take over 12 weeks earlier. Full integration is now expected to be completed by the end of February, per the filing.The firm said the transition included the transfer, restoration, and rebuilding of several processes and supply partnerships.The firm's shares fell past 2% in recent trading on Tuesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2493174756","title":"Rhythm Biosciences Completes Genetype Business Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2493174756","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493174756?lang=en_us&edition=fundamental","pubTime":"2024-12-24 10:24","pubTimestamp":1735007092,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  completed the acquisition of select Australian and US assets related to the Genetype business from Genetic Technologies  for AU$625,000, according to a Tuesday filing with the Australian bourse.The company paid the administrators of Genetic Technologies and select trade creditors the necessary cash amounts and assumed statutory employee entitlements for transferring employees in Australia, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7124","GTG.AU","RHY.AU","BK7048","XJO.AU","XAO.AU","XKO.AU"],"gpt_icon":0},{"id":"2493716711","title":"Rhythm Biosciences Ltd-Completion of Genetype Risk Assessment Portfolio Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2493716711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493716711?lang=en_us&edition=fundamental","pubTime":"2024-12-24 05:56","pubTimestamp":1734990983,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nTUE833YBG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RHY.AU","BK7124"],"gpt_icon":0},{"id":"2493274549","title":"BRIEF-Rhythm Biosciences Acquires Genetype Genetic Risk Assessment Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2493274549","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493274549?lang=en_us&edition=fundamental","pubTime":"2024-12-23 09:15","pubTimestamp":1734916513,"startTime":"0","endTime":"0","summary":"Dec 23 (Reuters) - Rhythm Biosciences Ltd   :   * RHY ACQUIRES GENETYPE GENETIC RISK ASSESSMENT BUSINESSFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2493202762","title":"ASX Alert-Rhy Acquires Genetype Genetic Risk Assessment Business-Rhy.ax","url":"https://stock-news.laohu8.com/highlight/detail?id=2493202762","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493202762?lang=en_us&edition=fundamental","pubTime":"2024-12-23 06:44","pubTimestamp":1734907466,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241222:nFWN3NM036:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2492455527","title":"Rhythm Biosciences Ltd - Trading Halt Requested Pending Proposed Acquisition Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2492455527","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492455527?lang=en_us&edition=fundamental","pubTime":"2024-12-20 10:17","pubTimestamp":1734661040,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nFWN3NK0WX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2492913234","title":"Rhythm Biosciences Ltd-Market Update - All End of Cy24 Milestones Attained","url":"https://stock-news.laohu8.com/highlight/detail?id=2492913234","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492913234?lang=en_us&edition=fundamental","pubTime":"2024-12-18 05:35","pubTimestamp":1734471312,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUE3ZFRCH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RHY.AU","BK7124"],"gpt_icon":0},{"id":"2484566361","title":"BRIEF-Rhythm Biosciences Says Susan Macleman Steps Down From Deputy Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2484566361","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484566361?lang=en_us&edition=fundamental","pubTime":"2024-11-20 14:05","pubTimestamp":1732082708,"startTime":"0","endTime":"0","summary":"BRIEF-Rhythm Biosciences Says Susan Macleman Steps Down From Deputy Chair Nov 20  - Rhythm Biosciences Ltd RHY.AX:BOARD COMPOSITION UPDATE - NED RESIGNATIONSSUSAN MACLEMAN STEPS DOWN FROM DEPUTY CHAIR TO NON-EXECUTIVE DIRECTORFurther company coverage: RHY.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUE88QFPZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHY.AU"],"gpt_icon":0},{"id":"2484918525","title":"Rhythm Biosciences Ltd-Board Composition Update - Ned Resignations","url":"https://stock-news.laohu8.com/highlight/detail?id=2484918525","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484918525?lang=en_us&edition=fundamental","pubTime":"2024-11-20 08:19","pubTimestamp":1732061954,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUE88QFPZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2484185797","title":"Rhythm Biosciences Ltd - Susan Macleman Steps Down From Deputy Chair to Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2484185797","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484185797?lang=en_us&edition=fundamental","pubTime":"2024-11-20 08:19","pubTimestamp":1732061954,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUE88QFPZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2484993303","title":"BRIEF-Rhythm Biosciences Says To Raise A$3.5 Million At A$0.10 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2484993303","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484993303?lang=en_us&edition=fundamental","pubTime":"2024-11-19 07:20","pubTimestamp":1731972036,"startTime":"0","endTime":"0","summary":"BRIEF-Rhythm Biosciences Says To Raise A$3.5 Million At A$0.10 Per ShareNov 19  - Rhythm Biosciences RHY.AX:RHYTHM BIOSCIENCES LTD-STRONG DEMAND IN SHARE PLACEMENT TO RAISE $3.5 MILLIONRHYTHM BIOSCIENCES LTD - TO RAISE A$3.5 MILLION AT A$0.10 PER SHARERHYTHM BIOSCIENCES LTD - ALL CURRENCIES IN AUDFurther company coverage: RHY.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUE1KVFHQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2484792933","title":"Rhythm Biosciences Ltd - All Currencies in AUD","url":"https://stock-news.laohu8.com/highlight/detail?id=2484792933","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484792933?lang=en_us&edition=fundamental","pubTime":"2024-11-19 07:19","pubTimestamp":1731971950,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUE1KVFHQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RHY.AU","BK7124"],"gpt_icon":0},{"id":"2484337199","title":"Rhythm Biosciences Ltd-Strong Demand in Share Placement to Raise $3.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2484337199","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484337199?lang=en_us&edition=fundamental","pubTime":"2024-11-19 07:19","pubTimestamp":1731971950,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUE1KVFHQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RHY.AU","BK7124"],"gpt_icon":0},{"id":"2483356017","title":"BRIEF-Rhythm Biosciences Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2483356017","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483356017?lang=en_us&edition=fundamental","pubTime":"2024-11-15 06:24","pubTimestamp":1731623070,"startTime":"0","endTime":"0","summary":"Nov 15 (Reuters) - Rhythm Biosciences Ltd   :   * TRADING HALT   * TRADING HALT DUE TO PROPOSED CAPITAL RAISING ANNOUNCEMENTFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RHY.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2020-07-27","symbol":"RHY.AU","type":"split","dateTimestamp":1595772000000,"forFactor":875,"toFactor":1000,"ratio":0.875}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RHY.AU\",market:\"AU\",,,undefined,":[]}}